Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Corteva is a pure-play agricultural inputs company formed from DowDuPont's 2019 spin-off, operating across seed (Pioneer corn/soy brands, ~45% revenue) and crop protection chemicals (~55% revenue). The company serves North American row crop farmers (60% of sales) and has leading market positions in corn seed (#1 globally) and selective herbicides, with pricing power driven by proprietary germplasm and trait technology.
Corteva monetizes proprietary germplasm through seed royalties and trait licensing (gross margins 50-55% in seed) while crop protection generates recurring revenue from farmers protecting planted acreage (gross margins 40-45%). Pricing power stems from multi-decade breeding programs creating yield-advantaged hybrids and herbicide-tolerant traits (Enlist E3 soybeans command $8-12/acre premiums). Operating leverage comes from fixed R&D ($1.8B annually) spread across expanding planted acres and channel inventory management driving working capital efficiency.
Corn and soybean planted acreage in North America (drives seed volumes and crop protection application rates)
Commodity grain prices (ZCUSX corn, ZSUSX soybeans) - higher prices improve farmer economics and willingness to pay for premium seed/chemicals
Enlist trait adoption rates and royalty capture (currently 50% of U.S. soy acres, targeting 70%+)
Crop protection pricing power and generic competition in key herbicide/insecticide categories
Brazilian safrinha corn acreage and Latin American market share gains
Weather patterns affecting planting windows and replant demand
Regulatory restrictions on crop protection active ingredients (EU bans on neonicotinoids, glyphosate litigation creating formulation risks) reducing addressable market
Gene editing technologies (CRISPR) potentially commoditizing trait development and eroding germplasm pricing power over 10+ year horizon
Climate volatility increasing weather-related demand swings and challenging yield consistency of seed products
Consolidation among farm retailers and cooperatives increasing buyer negotiating power
Bayer/BASF competition in herbicide-tolerant traits and dicamba/glyphosate formulations pressuring Enlist market share
Generic crop protection erosion in off-patent chemistries (chlorpyrifos alternatives, pyrethroid insecticides) compressing pricing 3-5% annually
Corteva lacks biotech trait diversity vs. Bayer (lacks insect resistance stacks), limiting bundling opportunities in corn
Pension and OPEB obligations inherited from DowDuPont legacy ($2.5B underfunded) creating cash drag
Environmental remediation liabilities from legacy Dow Chemical manufacturing sites
moderate - Revenue tied to global agricultural commodity cycles rather than GDP. High grain prices (driven by global food demand, biofuel mandates, weather) improve farmer profitability and input spending. However, seed purchases are relatively inelastic (farmers plant regardless of economics) while discretionary crop protection spending flexes with farm income. 60% exposure to U.S. row crops creates sensitivity to USDA acreage reports and crop insurance dynamics.
Low direct sensitivity but indirect impact through farmer financing costs and land values. Rising rates increase operating loan costs for farmers (reducing discretionary input budgets) and compress farmland values (weakening balance sheets). However, Corteva's own debt load is minimal (0.11 D/E) so corporate financing costs are negligible. Higher rates can strengthen USD, pressuring export demand for U.S. crops and farmer economics.
Minimal direct credit exposure. Corteva sells through distributors/retailers who manage farmer credit risk. Seasonal working capital builds in Q1 (channel stocking) but receivables are largely investment-grade ag retailers. Farmer credit stress could reduce demand for premium-priced products, but seed purchases are typically prioritized even in tight credit environments.
value - Trades at 10-12x EBITDA vs. specialty chemical peers at 14-16x, attracting investors seeking agricultural cycle exposure with improving margins from cost restructuring. 1.5% dividend yield appeals to income-focused funds. Recent 20%+ stock gains reflect multiple expansion as operating margin targets (18-20% EBITDA margin by 2025) gain credibility.
moderate - Beta ~1.1 with elevated volatility around USDA planting reports, quarterly earnings, and commodity price swings. Seasonal earnings pattern (60% of EBITDA in Q2-Q3) creates intra-year stock volatility. Less volatile than pure commodity plays but more cyclical than defensive staples.
